F. Poordad

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

F. Poordad, J.-P. Bronowicki, Stuart C. Gordon et al. · Journal of Hepatology · 2011 · 90 citations · Full text

Hepatology, Hepatitis C, Viral Hepatitis +11

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

F. Poordad, E. Läwitz, K.V. Kowdley et al. · Journal of Hepatology · 2012 · 65 citations

Viral Hepatitis, Immunodeficiencies, Immunology +9

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

K.V. Kowdley, E. Läwitz, F. Poordad et al. · Journal of Hepatology · 2013 · 56 citations · Full text

Viral Hepatitis, Antiviral Drug Development, Antiviral Therapy +6

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, F. Poordad, Ira M. Jacobson et al. · Journal of Hepatology · 2008 · 49 citations

Immunology, Antiviral Response, Antiviral Drug Development +6

13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS

E. Läwitz, F. Poordad, K.V. Kowdley et al. · Journal of Hepatology · 2012 · 43 citations

Viral Hepatitis, Immunology, Antiviral Therapy +8